Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

Abstract Background The phase I trial of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors was conducted recently. The present study identifies a potential prognostic biomarker for CD26-targeted therapy based on the phase I data. Methods Box and Whisker plot analysis, Scat...

Full description

Bibliographic Details
Main Authors: Yutaro Kaneko, Ryo Hatano, Naoto Hirota, Nicolas Isambert, Véronique Trillet-Lenoir, Benoit You, Jérôme Alexandre, Gérard Zalcman, Fanny Valleix, Thomas Podoll, Yoshimi Umezawa, Seiichi Takao, Satoshi Iwata, Osamu Hosono, Tetsuo Taguchi, Taketo Yamada, Nam H. Dang, Kei Ohnuma, Eric Angevin, Chikao Morimoto
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Biomarker Research
Subjects:
Serum soluble CD26/dipeptidyl peptidase 4
YS110
Prognostic biomarker
Cancer therapy
Online Access:https://doi.org/10.1186/s40364-021-00273-0

Internet

https://doi.org/10.1186/s40364-021-00273-0

Similar Items